A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma

Summary

This is a prospective, multicenter phase II trial designed to determine efficacy and safety of a chemoimmunotherapy with the combination of Bendamustine + Rituximab in patients with advanced untreated Indolent non Follicular non-Hodgkin Lymphomas (INFL).

Timeline

Start

2011-01

Primary completion

2012-03

Completion

2015-05

Drugs

Indications